Celprogen是一家生物技术公司，为心脏病学、肿瘤学、糖尿病和神经病学的再生医学研发干细胞研究和治疗产品。Celprogen的所有生物产品，包括干细胞、癌症干细胞、IPC和包括ECM在内的培养基，均在美国制造和生产。

CELPROGEN is a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media including ECM’s, are manufactured and produced in the United States of America. CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, Invitro diagnostics and academic partnership for drug discovery.

Celprogen公司的主要产品：

3D Culture Systems

Biological Reagents

Cell-Based Assay Kits

Cosmetic

Devices

ExtracellularMatrix

Human Serum Albumin (HSA)

Life Science

Normal Cells

Organ Cultures

Patient-Derived Xenografts [PDX]

Therapeutics

Tumorgenicity

Vaccine Development

Xeno-Free Media

Mediomics公司2001年成立，致力于为学术机构、制药公司、医学研究者、环境研究者提供创新性的检测试剂盒及生物感应物质。Mediomics拥有Patented Bridge-It® Assay Platform、Patented FRET-PINCER® Assay Platform、Patented TRF-PINCER® Assay Platform三大技术平台。

Mediomics, LLC provides innovative assay kits and biosensors needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets.  

Technology platforms:

（1）Patented Bridge-It® Assay Platform

Bridge-It® Assays are optimized to measure DNA binding proteins, their ligands, and co-regulators. Mediomics’ Bridge-It® assay was based on a simple idea of splitting the DNA binding site for a protein into two DNA half-sites. The presence of the DNA-binding protein or one of its ligands can be detected by FRET (fluorescence resonance energy transfer).

（2）Patented FRET-PINCER® Assay Platform

FRET-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected FRET-PINCER® Assay system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light through FRET (fluorescence resonance energy transfer).

（3）Patented TRF-PINCER® Assay Platform

TRF-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected TRF-PINCER® Assay platform system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light with Time-Resolved Fluorometry (TRF) sensitivity.

主要产品线包括：

（1）Bridge-It® Assay

（2）TR-FRET Bridge-It® Assay

（3）FRET-PINCER® Assay

（4）TR-FRET PINCER®Assay

（5）Other

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

KAMIYA公司旨在为生命科学和医疗机构提供高品质的创新的实验室研究和诊断工具。KAMIYA公司最早研发的产品是最前沿的用于信号转导研究的蛋白激酶抑制剂staurosporine（星形孢菌素）和K252a。1990年，KAMIYA成为美国第一家生产细胞凋亡研究的anti-Fas单克隆抗体的公司。如今，KAMIYA的产品线包括数千种人和动物临床前试验的生物标志物检测试试剂盒。此外,KAMIYA公司还为生命科学领域的研究着提供多种多样的酶抑制剂、单克隆抗体和多克隆抗体等产品，可用于研究细胞凋亡、耐药性、氧化、DNA损伤和修复、骨骼生物学、癌症、心脏病、炎症、肥胖症、糖尿病等研究。

KAMIYA公司K-ASSAY产品，用于胰岛素、血浆D-二聚体、凝血因子xiii、血浆FDP、血清/尿液 FPD、血清/尿液FDP-E、总IgE等指标的检测。KAMIYA现已发展成美国最大的脂质血清蛋白免疫分析试剂生厂商，为众多大型医院、医疗中心、临床实验室、临床参考实验室、科研机构、诊断试剂研发公司等机构提供优质的临床诊断试剂。

KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California and relocated to Seattle, Washington in 1996. Our company's purpose is supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com